Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms

被引:2
|
作者
Neculae, Gabriela [1 ,2 ]
Adam, Robert [1 ,2 ]
Jercan, Andreea [2 ,3 ]
Badelita, Sorina [3 ]
Tjahjadi, Catherina [4 ]
Draghici, Mirela [5 ]
Stan, Claudiu [6 ]
Bax, Jeroen J. [4 ]
Popescu, Bogdan A. [1 ,2 ]
Marsan, Nina Ajmone [4 ]
Coriu, Daniel [2 ,3 ]
Jurcut, Ruxandra [7 ,8 ]
机构
[1] Prof Dr CC Iliescu Emergency Inst Cardiovasc Dis, Expert Ctr Rare Cardiovasc Dis, Bucharest, Romania
[2] Carol Davila Univ Med & Pharm, Bucharest, Romania
[3] Fundeni Clin Inst, Dept Hematol, Bucharest, Romania
[4] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands
[5] Fundeni Clin Inst, Dept Neurol, Bucharest, Romania
[6] Fundeni Clin Inst, Dept Nucl Med, Bucharest, Romania
[7] Carol Davila Univ Med & Pharm, Expert Ctr Rare Cardiovasc Dis, Prof Dr CC Iliescu Emergency Inst Cardiovasc Dis, Bucharest, Romania
[8] Carol Davila Univ Med & Pharm, Euroecholab, Prof Dr CC Iliescu Emergency Inst Cardiovasc Dis, Bucharest, Romania
来源
ESC HEART FAILURE | 2024年 / 11卷 / 05期
关键词
AL amyloidosis; ATTR amyloidosis; Cardiac amyloidosis; Diagnostic score; Myocardial deformation; CONSENSUS DOCUMENT; AL AMYLOIDOSIS; DIAGNOSIS; ECHOCARDIOGRAPHY; STANDARDIZATION; DYSFUNCTION; BIOMARKERS; PROGNOSIS;
D O I
10.1002/ehf2.14852
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Systemic amyloidosis represents a heterogeneous group of diseases resulting from amyloid fibre deposition. The purpose of this study is to establish a differential diagnosis algorithm targeted towards the two most frequent subtypes of CA. Methods and results We prospectively included all consecutive patients with ATTR and AL evaluated between 2018 and 2022 in two centres in a score derivation cohort and a different validation sample. All patients had a complete clinical, biomarker, electrocardiographic, and imaging evaluation. Confirmation of the final diagnosis with amyloid typing was performed according to the current international recommendations. The study population included 81 patients divided into two groups: ATTR (group 1, n = 32: 28 variant and 4 wild type) and AL (group 2, n = 49). ATTR patients were younger (50.7 +/- 13.9 vs. 60.2 +/- 7.3 years, P = 0.0001), and significantly different in terms of NT-proBNP [ATTR: 1472.5 ng/L (97-4218.5) vs. AL 8024 ng/L (3058-14 069) P = 0.001], hs-cTn I [ATTR: 10 ng/L (4-20) vs. AL 78 ng/L (32-240), P = 0.0002], GFR [ATTR 95.4 mL/min (73.8-105.3) vs. AL: 68.4 mL/min (47.8-87.4) P = 0.003]. At similar left ventricular (LV) wall thickness and ejection fraction, the ATTR group had less frequently pericardial effusion (ATTR: 15% vs. AL: 33% P = 0.0027), better LV global longitudinal strain (ATTR: -13.1% +/- 3.5 vs. AL: -9.1% +/- 4.3 P = 0.04), RV strain (ATTR: -21.9% +/- 6.2 vs. AL: -16.8% +/- 6 P = 0.03) and better reservoir function of the LA strain (ATTR: 22% +/- 12 vs. AL: 13.6% +/- 7.8 P = 0.02). Cut-off points were calculated based on the Youden method. We attributed to 2 points for parameters having an AUC > 0.75 (NT-proBNP AUC 0.799; hs-cTnI AUC 0.87) and 1 point for GFR (AUC 0.749) and TTE parameters (GLS AUC 0.666; RV FWS AUC 0.649, LASr AUC 0.643). A score of equal or more than 4 points has been able to differentiate between AL and ATTR (sensitivity 80%, specificity 62%, AUC = 0.798). The differential diagnosis score system was applied to the validation cohort of 52 CA patients showing a sensitivity of 81% with specificity of 77%. Conclusions CA is a complex entity and requires extensive testing for a positive diagnosis. This study highlights a series of non-invasive checkpoints, which can be useful in guiding the decision-making process towards a more accurate and rapid differential diagnosis.
引用
收藏
页码:2481 / +
页数:977
相关论文
共 50 条
  • [21] Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study
    Fontana, Marianna
    Banypersad, Sanjay M.
    Treibel, Thomas A.
    Abdel-Gadir, Amna
    Maestrini, Viviana
    Lane, Thirusha
    Gilbertson, Janet A.
    Hutt, David F.
    Lachmann, Helen J.
    Whelan, Carol J.
    Wechalekar, Ashutosh D.
    Herrey, Anna S.
    Gillmore, Julian D.
    Hawkins, Philip N.
    Moon, James C.
    RADIOLOGY, 2015, 277 (02) : 388 - 397
  • [22] PLASMA CIRCULATING TRANSTHYRETIN FORMS IN PATIENTS WITH WILD TYPE TRANSTHYRETIN CARDIAC AMYLOIDOSIS
    Castiglione, Vincenzo
    Sanguinetti, Chiara
    Panichella, Giorgia
    Minniti, Marianna
    Caponi, Laura
    Aimo, Alberto
    Paolicchi, Aldo
    Emdin, Michele
    Vergaro, Giuseppe
    Franzini, Maria
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24
  • [23] Hepatocyte growth factor has prognostic utility in light chain and transthyretin cardiac amyloidosis
    Zhang, K. W.
    Kraja, A.
    Miao, J.
    Tomasek, K.
    Su, Y. R.
    Lenihan, D. J.
    EUROPEAN HEART JOURNAL, 2019, 40 : 652 - 652
  • [24] Light chain and transthyretin cardiac amyloidosis: Clinical characteristics, natural history and prognostic factors
    Barge-Caballero, Gonzalo
    Vazquez-Garcia, Raquel
    Barge-Caballero, Eduardo
    Couto-Mallon, David
    Paniagua-Martin, Maria J.
    Barriales-Villa, Roberto
    Pinon-Esteban, Pablo
    Bouzas-Mosquera, Alberto
    Pombo-Otero, Jorge
    Deben-Ariznavarreta, Guillermo
    Vazquez-Rodriguez, Jose M.
    Crespo-Leiro, Maria G.
    MEDICINA CLINICA, 2021, 156 (08): : 369 - 378
  • [25] Plasma Hepatocyte Growth Factor for Diagnosis and Prognosis in Light Chain and Transthyretin Cardiac Amyloidosis
    Zhang, Kathleen W.
    Miao, Jennifer
    Mitchell, Joshua D.
    Alvarez-Cardona, Jose
    Tomasek, Kelsey
    Su, Yan Ru
    Gordon, Mary
    Cornell, R. Frank
    Lenihan, Daniel J.
    JACC: CARDIOONCOLOGY, 2020, 2 (01): : 56 - 66
  • [26] Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis
    Cappelli, Francesco
    Vignini, Elisa
    Martone, Raffaele
    Perlini, Stefano
    Mussinelli, Roberta
    Sabena, Anna
    Morini, Sofia
    Gabriele, Martina
    Taborchi, Giulia
    Bartolini, Simone
    Lossi, Angelica
    Nardi, Giulia
    Marchionni, Niccolo
    Di Mario, Carlo
    Olivotto, Iacopo
    Perfetto, Federico
    CIRCULATION-HEART FAILURE, 2020, 13 (03)
  • [27] Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis
    Porcari, Aldostefano
    Rossi, Maddalena
    Cappelli, Francesco
    Canepa, Marco
    Musumeci, Beatrice
    Cipriani, Alberto
    Tini, Giacomo
    Barbati, Giulia
    Varra, Guerino Giuseppe
    Morelli, Cristina
    Fumagalli, Carlo
    Zampieri, Mattia
    Argiro, Alessia
    Vianello, Pier Filippo
    Sessarego, Eugenio
    Russo, Domitilla
    Sinigiani, Giulio
    De Michieli, Laura
    Di Bella, Gianluca
    Autore, Camillo
    Perfetto, Federico
    Rapezzi, Claudio
    Sinagra, Gianfranco
    Merlo, Marco
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (07) : 1227 - 1236
  • [28] Clinical differences between transthyretin cardiac amyloidosis and hypertensive heart disease
    Gallo-Fernandez, Ignacio
    Lopez-Aguilera, Jose
    Gonzalez-Manzanares, Rafael
    Pericet-Rodriguez, Cristina
    Carmona-Rico, Manuel Jesus
    Perea-Armijo, Jorge
    Castillo-Dominguez, Juan Carlos
    Anguita-Sanchez, Manuel
    MEDICINA CLINICA, 2024, 162 (05): : 205 - 212
  • [29] The prognostic value of multiparametric cardiac magnetic resonance in patients with systemic light chain amyloidosis
    Miao, Fujia
    Tang, Chunxiang
    Ren, Guisheng
    Guo, Jinzhou
    Zhao, Liang
    Xu, Weiwei
    Zhou, Xiyang
    Zhang, Longjiang
    Huang, Xianghua
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] Differences in the characteristics and contemporary cardiac outcomes of patients with light-chain versus transthyretin cardiac amyloidosis
    Itzhaki Ben Zadok, Osnat
    Vaturi, Mordehay
    Vaxman, Iuliana
    Iakobishvili, Zaza
    Rhurman-Shahar, Noa
    Kornowski, Ran
    Hamdan, Ashraf
    PLOS ONE, 2021, 16 (08):